ABGENERATE Trademark

Trademark Overview

On Tuesday, May 29, 2001, a trademark application was filed for ABGENERATE with the United States Patent and Trademark Office. The USPTO has given the ABGENERATE trademark a serial number of 76263186. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Monday, May 20, 2002. This trademark is owned by AbGenomics Corporation. The ABGENERATE trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Stimulation of immune response and generation of antibodies in animal services/specially designed protocal (form of presentation of antigen, doses, routes of injections, schedule of injections)
abgenerate

General Information

Serial Number76263186
Word MarkABGENERATE
Filing DateTuesday, May 29, 2001
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateMonday, May 20, 2002
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesStimulation of immune response and generation of antibodies in animal services/specially designed protocal (form of presentation of antigen, doses, routes of injections, schedule of injections)
Pseudo MarkAB GENERATE

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, June 8, 2001
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAbGenomics Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressTaipei
TW

Trademark Events

Event DateEvent Description
Monday, May 20, 2002ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Tuesday, August 7, 2001NON-FINAL ACTION MAILED
Friday, July 27, 2001ASSIGNED TO EXAMINER
Wednesday, July 25, 2001ASSIGNED TO EXAMINER

Related Keywords

abgenerate injections presentation form antigen routes schedule protocal doses designed generation